Ipamorelin

Ipamorelin is a synthetic pentapeptide and highly selective growth hormone secretagogue (GHS) that acts specifically on the GHS-R1a receptor. Unlike other GHRPs, it selectively stimulates pituitary GH release without affecting other hormones like ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses up to 200× the ED50 for GH.

Selective GH Stimulation: Stimulates GH without raising cortisol, ACTH, prolactin, or other pituitary hormones
Physiological GH Release: Maintains natural pulsatile patterns; mimics endogenous GH cycles
Reduced Injection Frequency: Longer half-life allows fewer injections compared to GHRP-2 or GHRP-6
Safety Profile: Mild, transient side effects; lower risk than non-selective GHRPs
Tissue Repair & Recovery: GH-mediated pathways may enhance wound healing, recovery from injury, and anabolic signaling
Body Composition: Potential benefits via GH/IGF-1 pathways (lean mass, fat metabolism)
Sleep Architecture: May improve slow-wave sleep indirectly through GH release (animal data; limited human studies)
Metabolic Effects: Potential glucose and lipid metabolism benefits via GH pathways (preclinical/animal data)

Gobburu JV, et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res, 16(9), 1412-1416. PMID: 10496658
Beck DE, et al. (2014). Prospective, randomized, controlled study of ipamorelin for postoperative ileus management. Int J Colorectal Dis, 29(12), 1527-1534. PMID: 25331030
Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5), 552-561. PMID: 9849822
Johansen PB, et al. (1998). Pharmacokinetics of ipamorelin and other peptidyl GHS, emphasis on nasal absorption. Xenobiotica, 28(11), 1083-1092. PMID: 9879640
Ishida J, et al. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun, 3(1), 25-37. DOI

$75.00

Per Unit

In stock